Mereo BioPharma Group plc: Form 10-K for the period ended Dec 31, 2023
Filed with the SEC on Mar 27, 2024 and accepted by EDGAR at Mar 27, 2024, 17:20 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2023-01-01 to 2023-12-31 | $10.0m | us-gaap:Revenues |
| Research and development | 12 months2023-01-01 to 2023-12-31 | $17.4m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months2023-01-01 to 2023-12-31 | −$28.4m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2023-01-01 to 2023-12-31 | $2.9m | us-gaap:InterestExpense |
| Income tax | 12 months2023-01-01 to 2023-12-31 | −$532.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2023-01-01 to 2023-12-31 | −$29.5m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2023-01-01 to 2023-12-31 | −$0.04 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2023-01-01 to 2023-12-31 | −$0.04 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2023-01-01 to 2023-12-31 | 659,453,921 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2023-01-01 to 2023-12-31 | −$21.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2023-01-01 to 2023-12-31 | $0 | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2023-12-31 | $57.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-12-31 | $63.8m | us-gaap:AssetsCurrent |
| Total assets | At period end2023-12-31 | $66.5m | us-gaap:Assets |
| Current liabilities | At period end2023-12-31 | $9.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-12-31 | $16.0m | us-gaap:Liabilities |
| Shareholders' equity | At period end2023-12-31 | $50.5m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000950170-24-037348. Last ingested by Listed: Oct 24, 2026, 15:15 ET. Listed shows no prices and gives no investment advice.